At #ATS2026, we’ll share the baseline characteristics results from a Phase 3 trial, key data and real-world learnings from multiple studies across idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). Learn more about our latest work and how we’re advancing research: https://bit.ly/4v3FArZ #PulmonaryFibrosis
Bristol Myers Squibb
Pharmaceutical Manufacturing
Lawrence Township, NJ 1,878,521 followers
About us
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html
- Website
-
http://www.bms.com
External link for Bristol Myers Squibb
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Lawrence Township, NJ
- Type
- Public Company
- Specialties
- biotechnology, innovation, great place to work, pharmaceuticals, research and development, and healthcare
Locations
Employees at Bristol Myers Squibb
Updates
-
Jean-Michel’s life changed after his idiopathic pulmonary fibrosis (IPF) diagnosis in 2017. Since then, he’s turned that experience into resilience and advocacy, helping shine a light on what life with IPF can look like beyond the diagnosis, and why there’s still more work to do. Today, he’s advocating for earlier diagnosis and better support for patients and caregivers. Read Jean-Michel’s story: https://bit.ly/4uRnlpi #ATS2026 #OneBMS
-
-
Bristol Myers Squibb reposted this
Advancing drug development today demands more than scientific excellence. It requires new ways of connecting expertise, sharing insights, and learning from one another at scale. That’s exactly what we set out to do with our first Drug Development Expo at Bristol Myers Squibb. With Princeton Pike and Hyderabad as our host sites, and colleagues joining from across our global organization, we created a truly connected experience by bringing together teams to exchange ideas, challenge thinking, and showcase the work that is moving our pipeline forward. We were also pleased to welcome Daniel Burkhardt from NVIDIA, whose perspective underscored how advances in AI and technology are shaping the future of drug development and the importance of bringing scientific and technical expertise closer together. What stood out most was the energy and curiosity across the organization. Across disciplines, geographies, and perspectives, teams leaned into open dialogue and practical problem-solving — a reminder that innovation doesn’t happen in isolation. The Expo reinforced what makes our organization unique: the ability to bring together deep scientific expertise with a culture of collaboration and continuous learning. If you’re motivated by solving complex problems, working across boundaries, and translating science into meaningful outcomes for patients, there’s never been a more exciting time to be part of this work. #ProudToBeBMS
-
-
Today, we announced a strategic agreement with Anthropic to advance the use of AI across our global operations and position Claude Enterprise as our shared intelligence platform. By combining our scientific expertise with Anthropic’s frontier AI, we aim to accelerate the discovery, development and delivery of transformational medicines by empowering our 30,000+ colleagues with advanced reasoning and agentic capabilities to better access data, generate insights and work more efficiently across the enterprise. This agreement marks an evolution in how we deploy AI — moving beyond the conversational tools that defined the first wave of adoption to agentic tools that better connect our people, systems and knowledge at scale. Learn more: https://bit.ly/4tLJrsy #OneBMS
-
A medicine can be scientifically groundbreaking – and still be hard to use in real life. That’s why our Product Development team looks beyond the molecule, designing with the full patient experience in mind: how a therapy is packaged, how it’s administered and how patients and caregivers interact with it day-to-day. Learn more about our patient-driven product design: https://bit.ly/4dkA91O #OneBMS
-
We remain dedicated to helping improve outcomes for patients facing melanoma through innovative research that can impact lives like Mary Elizabeth’s, a patient and clinical trial participant. Melanoma is the most serious form of skin cancer, posing a public health challenge globally. While often associated with sun exposure, understanding all risk factors and prioritizing early detection is essential for people of all ages. Read Mary Elizabeth’s story of diagnosis, recurrence and partnership with her healthcare team to find the right care for her, underscoring the importance of patient empowerment: https://bit.ly/42Idx55 #OneBMS #MelanomaAwarenessMonth
-
We are deepening our understanding of brain health through ongoing research in complex psychiatric conditions, like schizophrenia. At this year's American Psychiatric Association Annual Meeting, our teams are contributing to the scientific conversation by presenting data from our clinical research program, including findings on patient characteristics, treatment patterns and disease outcomes. We remain committed to advancing the science that supports meaningful progress in psychiatric care. Learn more about our work in neuroscience: https://bit.ly/4uOowWB #APAAM26 #OneBMS
-
-
We’re advancing research that looks at the biology of pulmonary fibrosis (PF) – with the goal of making a bigger difference for people living with this disease. Today’s treatments can slow the loss of lung function, but many people still need better options. One area we’re investigating is a target called lysophosphatidic acid receptor 1 (LPA1). Learn more: https://bit.ly/4uTyeHq #ATS2026 #OneBMS
-
Our teams are focused on developing therapies that aim to modify the course of disease and help address symptoms for people living with neurological and psychiatric conditions. We look forward to connecting with peers at the American Psychiatric Association Annual Meeting to exchange insights and explore scientific advancements in the field. Learn more about our neuroscience research: https://bit.ly/4eIOHt6 #APAAM26 #OneBMS
-
-
Scientific progress is built on persistence. It’s the drive to keep learning, keep improving and keep pushing forward, even when breakthroughs don’t come easily. We’re advancing research by combining human ingenuity with AI and emerging technologies to help bring new medicines to patients faster. It’s how we stay focused on what matters most and why We Won’t Lose. See how we’re focusing on the science most likely to make a meaningful difference for patients: https://bit.ly/3Rr6Thb #ScienceFirsthand #OneBMS #BMSWontLose